Cargando…
Assessing cough symptom severity in refractory or unexplained chronic cough: findings from patient focus groups and an international expert panel
BACKGROUND: Cough symptom severity represents an important subjective end-point to assess the impact of therapies for patients with refractory or unexplained chronic cough (RCC/UCC). As existing instruments assessing the severity of cough are neither widely available nor tested for measurement prope...
Autores principales: | Kum, Elena, Guyatt, Gordon H., Munoz, Caroline, Beaudin, Suzanne, Li, Shelly-Anne, Abdulqawi, Rayid, Badri, Huda, Boulet, Louis-Philippe, Chen, Ruchong, Dicpinigaitis, Peter, Dupont, Lieven, Field, Stephen K., French, Cynthia L., Gibson, Peter G., Irwin, Richard S., Marsden, Paul, McGarvey, Lorcan, Smith, Jaclyn A., Song, Woo-Jung, O'Byrne, Paul M., Satia, Imran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8918938/ https://www.ncbi.nlm.nih.gov/pubmed/35295233 http://dx.doi.org/10.1183/23120541.00667-2021 |
Ejemplares similares
-
Chronic cough: new insights and future prospects
por: Morice, Alyn, et al.
Publicado: (2021) -
Mechanisms and Rationale for Targeted Therapies in Refractory and Unexplained Chronic Cough
por: Mazzone, Stuart B., et al.
Publicado: (2020) -
Cough symptom severity in patients with refractory or unexplained chronic cough: a systematic survey and conceptual framework
por: Kum, Elena, et al.
Publicado: (2021) -
Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough
por: Muccino, David R., et al.
Publicado: (2020) -
An open-label study of the tolerability and potential efficacy of memantine for treating refractory chronic cough
por: Abdulqawi, Rayid, et al.
Publicado: (2021)